Lowest Price Guaranteed
Pages
291
Last Updated
June 2026
View Count
19710
1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Long Acting Drug Delivery
3.2.1. Types of Long Acting Drug Delivery Systems
3.3. Long Acting Drug Delivery Technologies
3.3.1. Underlying Principle
3.3.2. Associated Strategies
3.4. Concluding Remarks
4. TECHNOLOGY LANDSCAPE
4.1. Chapter Overview
4.2. Long Acting Drug Delivery: Technology Landscape
4.2.1. Analysis by Principle
4.2.2. Analysis by Strategy
4.2.3. Analysis by Type of Material Used
4.2.4. Analysis by Compatible Dosage Form(s)
4.2.5. Analysis by Extended Dosing Interval(s)
4.2.6. Analysis by Type of Molecule(s) Delivered
4.2.7. Analysis by Highest Phase of Development
4.2.8. Analysis by Number of Approved Drugs
4.2.9. Analysis by Therapeutic Area(s)
4.3. Long Acting Drug Delivery: Technology Developers Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Most Active Players: Analysis by Number of Technologies
5. SERVICE PROVIDERS LANDSCAPE
5.1. Chapter Overview
5.2. Long Acting Drug Delivery: Service Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Analysis by Location of Facilities
5.2.6. Analysis by Type of Service Provider(s)
5.2.7. Analysis by Scale of Operation
5.2.8. Analysis by Compatible Dosage Form(s)
5.2.9. Analysis by Scale of Operation and Compatible Dosage Form(s)
5.2.10. Analysis by Service(s) Offered
5.2.11. Analysis by Company Size and Service(s) Offered
5.2.12. Analysis by Year of Establishment, Location of Headquarters and Service(s) Offered
5.2.13. Analysis by Type of Molecule(s) Supported
5.2.14. Analysis by Type of Service Provider(s) and Type of Molecule(s) Supported
6. TECHNOLOGY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions / Key Parameters
6.3. Methodology
6.4. Technology Competitiveness Analysis
6.4.1. Long Acting Drug Delivery Technologies offered by Small Companies
6.4.2. Long Acting Drug Delivery Technologies offered by Mid-sized Companies
6.4.3. Long Acting Drug Delivery Technologies offered by Large Companies
6.4.4. Long Acting Drug Delivery Technologies offered by Very Large Companies
7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions / Key Parameters
7.3. Methodology
7.4. Company Competitiveness Analysis
7.4.1. Long Acting Drug Delivery Service Providers based in North America
7.4.2. Long Acting Drug Delivery Service Providers based in Europe
7.4.3. Long Acting Drug Delivery Service Providers based in Asia-Pacific
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Adare Pharma Solutions
8.2.1. Company Overview
8.2.2. Technology Portfolio
8.2.3. Service Portfolio
8.2.4. Recent Developments and Future Outlook
8.3. AMW
8.3.1. Company Overview
8.3.2. Technology Portfolio
8.3.3. Service Portfolio
8.3.4. Recent Developments and Future Outlook
8.4. Bostal Drug Delivery
8.4.1. Company Overview
8.4.2. Technology Portfolio
8.4.3. Service Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. Creative Biolabs
8.5.1. Company Overview
8.5.2. Technology Portfolio
8.5.3. Service Portfolio
8.5.4. Recent Developments and Future Outlook
8.6. ForDoz Pharma
8.6.1. Company Overview
8.6.2. Technology Portfolio
8.6.3. Service Portfolio
8.6.4. Recent Developments and Future Outlook
8.7. InnoCore Pharmaceuticals
8.7.1. Company Overview
8.7.2. Technology Portfolio
8.7.3. Service Portfolio
8.7.4. Recent Developments and Future Outlook
8.8. Integral BioSystems
8.8.1. Company Overview
8.8.2. Technology Portfolio
8.8.3. Service Portfolio
8.8.4. Recent Developments and Future Outlook
8.9. LATITUDE Pharmaceuticals
8.9.1. Company Overview
8.9.2. Technology Portfolio
8.9.3. Service Portfolio
8.9.4. Recent Developments and Future Outlook
8.10. Navin Saxena Research and Technology Centre (NSRT)
8.10.1. Company Overview
8.10.2. Technology Portfolio
8.10.3. Service Portfolio
8.10.4. Recent Developments and Future Outlook
8.11. Samyang Biopharm
8.11.1. Company Overview
8.11.2. Technology Portfolio
8.11.3. Service Portfolio
8.11.4. Recent Developments and Future Outlook
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Long Acting Drug Delivery Technologies and Services: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Location of Headquarters of Partner
9.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Regional Analysis
9.3.8.1. Intercontinental and Intracontinental Deals
9.3.8.2. Local and International Deals
10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Long Acting Drug Delivery: Publication Analysis
10.3.1. Analysis by Year of Publication
10.3.2. Analysis by Type of Publication
10.3.3. Analysis by Most Popular Keywords
10.3.4. Most Popular Journals: Analysis by Number of Publications
10.3.5. Most Popular Publishers: Analysis by Number of Publications
10.3.6. Most Popular Copyright Holders: Analysis by Number of Publications
10.3.7. Key Funding Institutes: Analysis by Number of Publications
11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Long Acting Drug Delivery: Patent Analysis
11.3.1. Analysis by Publication Year
11.3.2. Analysis by Type of Patent and Publication Year
11.3.3. Analysis by Geography
11.3.4. Analysis by CPC Symbols
11.3.5. Leading Industry Players: Analysis by Number of Patents
11.3.6. Analysis by Type of Organization
11.4. Patent Benchmark Analysis
11.4.1. Analysis by Patent Characteristics
11.5. Patent Valuation Analysis
12. GRANT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Long Acting Drug Delivery: Grant Analysis
12.3.1. Analysis by Year of Grant Award
12.3.2. Analysis by Amount Awarded
12.3.3. Analysis by Support Period
12.3.4. Analysis by Support Period and Funding Institute Center
12.3.5. Analysis by Type of Grant Application
12.3.6. Analysis by Purpose of Grant Award
12.3.7. Analysis By Activity Code
12.3.8. Analysis by NIH Spending Category
12.3.9. Analysis by Study Section Involved
12.3.10. Popular NIH Departments: Analysis by Number of Grants
12.3.11. Analysis by Type of Recipient Organization
12.3.12. Prominent Program Officers: Analysis by Number of Grants
12.3.13. Popular Recipient Organizations: Analysis by Number of Grants
12.3.14. Popular Recipient Organizations: Analysis by Grant Amount
12.3.15. Analysis by Region of Recipient Organizations
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global Long Acting Drug Delivery Technologies Market, 2023-2035
13.3.1. Long Acting Drug Delivery Technologies Market: Analysis by Type of Payment Model Employed
13.3.1.1. Long Acting Drug Delivery Technologies Market for Upfront Payment, 2023-2035
13.3.1.2. Long Acting Drug Delivery Technologies Market for Milestone Payment, 2023-2035
13.3.2. Long Acting Drug Delivery Technologies Market: Analysis by Principle
13.3.2.1. Long Acting Drug Delivery Technologies Market for Manipulation of Drug Release from Delivery Systems, 2023-2035
13.3.2.2. Long Acting Drug Delivery Technologies Market for Manipulation of In Vivo Clearance, 2023-2035
13.3.3. Long Acting Drug Delivery Technologies Market: Analysis by Strategy
13.3.3.1. Long Acting Drug Delivery Technologies Market for Micro-encapsulation, 2023-2035
13.3.3.2. Long Acting Drug Delivery Technologies Market for Long Acting Implants, 2023-2035
13.3.3.3. Long Acting Drug Delivery Technologies Market for Multivesicular Liposomes, 2023-2035
13.3.3.4. Long Acting Drug Delivery Technologies Market for Nanocrystal Suspensions, 2023-2035
13.3.3.5. Long Acting Drug Delivery Technologies Market for Long Acting Hydrogels, 2023-2035
13.3.3.6. Long Acting Drug Delivery Technologies Market for Long Acting Microneedles, 2023-2035
13.3.3.7. Long Acting Drug Delivery Technologies Market for Chemical Modification, 2023-2035
13.3.3.8. Long Acting Drug Delivery Technologies Market for Protein Fusion, 2023-2035
13.3.4. Long Acting Drug Delivery Technologies Market: Analysis by Compatible Dosage Form
13.3.4.1. Long Acting Drug Delivery Technologies Market for Injectables, 2023-2035
13.3.4.2. Long Acting Drug Delivery Technologies Market for Implantables, 2023-2035
13.3.4.3. Long Acting Drug Delivery Technologies Market for Vaginal Dosage Forms, 2023-2035
13.3.4.4. Long Acting Drug Delivery Technologies Market for Topical / Transdermal Dosage Forms, 2023-2035
13.3.4.5. Long Acting Drug Delivery Technologies Market for Oral Dosage Forms, 2023-2035
13.3.4.6. Long Acting Drug Delivery Technologies Market for Other Dosage Forms, 2023-2035
13.3.5. Long Acting Drug Delivery Technologies Market: Analysis by Type of Molecule Delivered
13.3.5.1. Long Acting Drug Delivery Technologies Market for Small Molecules, 2023-2035
13.3.5.2. Long Acting Drug Delivery Technologies Market for Biologics, 2023-2035
13.3.5.3. Long Acting Drug Delivery Technologies Market for Other Molecules, 2023-2035
13.3.6. Long Acting Drug Delivery Technologies Market: Analysis by Type of Material Used
13.3.6.1. Long Acting Drug Delivery Technologies Market for Polymer-based, 2023-2035
13.3.6.2. Long Acting Drug Delivery Technologies Market for Non-polymer based, 2023-2035
13.3.7. Long Acting Drug Delivery Technologies Market: Analysis by Region
13.3.7.1. Long Acting Drug Delivery Technologies Market in North America, 2023-2035
13.3.7.2. Long Acting Drug Delivery Technologies Market in Europe, 2023-2035
13.3.7.3. Long Acting Drug Delivery Technologies Market in Asia-Pacific, 2023-2035
13.3.7.4. Long Acting Drug Delivery Technologies Market in Middle East and North Africa, 2023-2035
13.4. Global Long Acting Drug Delivery Services Market, 2023-2035
13.4.1. Long Acting Drug Delivery Services Market: Analysis by Compatible Dosage Form
13.4.1.1. Long Acting Drug Delivery Services Market for Injectables, 2023-2035
13.4.1.2. Long Acting Drug Delivery Services Market for Implantables, 2023-2035
13.4.1.3. Long Acting Drug Delivery Services Market for Vaginal Dosage Forms, 2023-2035
13.4.1.4. Long Acting Drug Delivery Services Market for Topical / Transdermal Dosage Forms, 2023-2035
13.4.1.5. Long Acting Drug Delivery Services Market for Oral Dosage Forms, 2023-2035
13.4.1.6. Long Acting Drug Delivery Services Market for Other Dosage Forms, 2023-2035
13.4.2. Long Acting Drug Delivery Services Market: Analysis by Type of Molecule Supported
13.4.2.1. Long Acting Drug Delivery Services Market for Small Molecules, 2023-2035
13.4.2.2. Long Acting Drug Delivery Services Market for Biologics, 2023-2035
13.4.2.3. Long Acting Drug Delivery Services Market for Other Molecules, 2023-2035
13.4.3. Long Acting Drug Delivery Services Market: Analysis by Region
13.4.3.1. Long Acting Drug Delivery Services Market in North America, 2023-2035
13.4.3.2. Long Acting Drug Delivery Services Market in Europe, 2023-2035
13.4.3.3. Long Acting Drug Delivery Services Market in Asia-Pacific, 2023-2035
14. CONCLUSION
15. INTERVIEW TRANSCRIPTS
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Technology Landscape
Figure 2.1 Executive Summary: Technology Landscape
Figure 2.2 Executive Summary: Service Providers Landscape
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Publication Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Grant Analysis
Figure 2.7 Executive Summary: Market Forecast and Opportunity Analysis (Technology)
Figure 2.8 Executive Summary: Market Forecast and Opportunity Analysis (Service)
Figure 3.1 Types of Long Acting Drug Delivery Systems
Figure 3.2 Principles and Strategies associated with Long Acting Drug Delivery
Figure 4.1 LADD Technologies: Distribution by Principle
Figure 4.2 LADD Technologies: Distribution by Strategy
Figure 4.3 LADD Technologies: Distribution by Type of Material Used
Figure 4.4 LADD Technologies: Distribution by Compatible Dosage Form(s)
Figure 4.5 LADD Technologies: Distribution by Extended Dosing Interval(s)
Figure 4.6 LADD Technologies: Distribution by Type of Molecule(s) Delivered
Figure 4.7 LADD Technologies: Distribution by Highest Phase of Development
Figure 4.8 LADD Technologies: Distribution by Number of Approved Drugs
Figure 4.9 LADD Technologies: Distribution by Therapeutic Area(s)
Figure 4.10 LADD Technology Developers: Distribution by Year of Establishment
Figure 4.11 LADD Technology Developers: Distribution by Company Size
Figure 4.12 LADD Technology Developers: Distribution by Location of Headquarters
Figure 4.13 Most Active Players: Distribution by Number of Technologies
Figure 5.1 LADD Contract Service Providers: Distribution by Year of Establishment
Figure 5.2 LADD Contract Service Providers: Distribution by Company Size
Figure 5.3 LADD Contract Service Providers: Distribution by Location of Headquarters
Figure 5.4 LADD Contract Service Providers: Distribution by Company Size and Location of Headquarters
Figure 5.5 LADD Contract Service Providers: Distribution by Location of Facilities
Figure 5.6 LADD Contract Service Providers: Distribution by Type of Service Provider(s)
Figure 5.7 LADD Contract Service Providers: Distribution by Scale of Operation
Figure 5.8 LADD Contract Service Providers: Distribution by Compatible Dosage Form(s)
Figure 5.9 LADD Contract Service Providers: Distribution by Scale of Operation and Compatible Dosage Form(s)
Figure 5.10 LADD Contract Service Providers: Distribution by Service(s) Offered
Figure 5.11 LADD Contract Service Providers: Distribution by Company Size and Service(s) Offered
Figure 5.12 LADD Contract Service Providers: Distribution by Year of Establishment, Location of Headquarters and Service(s) Offered
Figure 5.13 LADD Contract Service Providers: Distribution by Type of Molecule(s) Supported
Figure 5.14 LADD Contract Service Providers: Distribution by Type of Service Provider(s) and Type of Molecule(s) Supported
Figure 6.1 Technology Competitiveness Analysis: LADD Technologies offered by Small Companies
Figure 6.2 Technology Competitiveness Analysis: LADD Technologies offered by Mid-sized Companies
Figure 6.3 Technology Competitiveness Analysis: LADD Technologies offered by Large Companies
Figure 6.4 Technology Competitiveness Analysis: LADD Technologies offered by Very Large Companies
Figure 7.1 Company Competitiveness Analysis: LADD Service Providers based in North America
Figure 7.2 Company Competitiveness Analysis: LADD Service Providers based in Europe
Figure 7.3 Company Competitiveness Analysis: LADD Service Providers based in Asia-Pacific
Figure 8.1 Adare Pharma Solutions: Service Portfolio
Figure 8.2 AMW: Service Portfolio
Figure 8.3 Bostal Drug Delivery: Service Portfolio
Figure 8.4 Creative Biolabs: Service Portfolio
Figure 8.5 ForDoz Pharma: Service Portfolio
Figure 8.6 InnoCore Pharmaceuticals: Service Portfolio
Figure 8.7 Integral BioSystems: Service Portfolio
Figure 8.8 LATITUDE Pharmaceuticals: Service Portfolio
Figure 8.9 Navin Saxena Research and Technology Centre (NSRT): Service Portfolio
Figure 8.10 Samyang Biopharm: Service Portfolio
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2022
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.5 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Headquarters of Partner
Figure 9.7 Most Active Players: Distribution by Number of Partnerships
Figure 9.8 Partnerships and Collaborations: Regional Distribution
Figure 9.9 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 9.10 Partnerships and Collaborations: Local and International Deals
Figure 10.1 Publication Analysis: Cumulative Year-wise Trend, 2017-2022
Figure 10.2 Publication Analysis: Distribution by Type of Publication
Figure 10.3 Most Popular Journals: Distribution by Number of Publications
Figure 10.4 Most Popular Publishers: Distribution by Number of Publications
Figure 10.5 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 10.6 Most Popular Keywords: Distribution by Number of Publications
Figure 10.7 Key Funding Institutes: Distribution by Number of Publications
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Publication Year, 2018-2022
Figure 11.3 Patent Analysis: Distribution by Type of Patent and Publication Year
Figure 11.4 Patent Analysis: Distribution by Geography
Figure 11.5 Patent Analysis: Distribution by CPC Symbols
Figure 11.6 Leading Industry Players: Distribution by Number of Patents
Figure 11.7 Patent Analysis: Cumulative Distribution by Type of Organization
Figure 11.8 Leading Industrial Players: Benchmarking by Patent Characteristics (CPC Codes)
Figure 11.9 Patent Analysis: Distribution by Patent Age (2018-2022)
Figure 11.10 Patent Analysis: Patent Valuation
Figure 12.1 Grant Analysis: Cumulative Trend by Year of Grant, 2018-2022
Figure 12.2 Grant Analysis: Distribution by Cumulative Amount Awarded (USD Million), 2018-2022
Figure 12.3 Grant Analysis: Distribution by Support Period
Figure 12.4 Grant Analysis: Distribution by Support Period and Funding Institute Center
Figure 12.5 Grant Analysis: Distribution by Type of Grant Application
Figure 12.6 Grant Analysis: Distribution by Purpose of Grant Award
Figure 12.7 Grant Analysis: Distribution by Activity Code
Figure 12.8 Word Cloud: NIH Spending Category
Figure 12.9 Grant Analysis: Distribution by Study Section Involved
Figure 12.10 Popular NIH Departments: Distribution by Number of Grants
Figure 12.11 Grant Analysis: Distribution by Type of Recipient Organization
Figure 12.12 Prominent Program Officers: Distribution by Number of Grants
Figure 12.13 Popular Recipient Organizations: Distribution by Number of Grants
Figure 12.14 Popular Recipient Organization: Distribution by Grant Amount (USD Million)
Figure 12.15 Grant Analysis: Distribution by Region of Recipient Organization
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 13.2 Licensing Agreements: Illustrative Scenario based Opportunity Estimation
Figure 13.3 Global Long Acting Drug Delivery Technologies Market, 2023-2035 (USD Billion)
Figure 13.4 Long Acting Drug Delivery Technologies Market: Distribution by Type of Payment Model Employed, 2023, 2030 and 2035
Figure 13.5 Long Acting Drug Delivery Technologies Market for Upfront Payment, 2023-2035 (USD Billion)
Figure 13.6 Long Acting Drug Delivery Technologies Market for Milestone Payment, 2023-2035 (USD Billion)
Figure 13.7 Long Acting Drug Delivery Technologies Market: Distribution by Principle, 2023, 2030 and 2035
Figure 13.8 Long Acting Drug Delivery Technologies Market for Manipulation of Drug Release from Delivery Systems, 2023-2035 (USD Billion)
Figure 13.9 Long Acting Drug Delivery Technologies Market for Manipulation of In Vivo Clearance, 2023-2035 (USD Billion)
Figure 13.10 Long Acting Drug Delivery Technologies Market: Distribution by Strategy, 2023, 2030 and 2035
Figure 13.11 Long Acting Drug Delivery Technologies Market for Micro-encapsulation, 2023-2035 (USD Billion)
Figure 13.12 Long Acting Drug Delivery Technologies Market for Long Acting Implants, 2023-2035 (USD Billion)
Figure 13.13 Long Acting Drug Delivery Technologies Market for Multivesicular Liposomes, 2023-2035
Figure 13.14 Long Acting Drug Delivery Technologies Market for Nanocrystal Suspensions, 2023-2035 (USD Billion)
Figure 13.15 Long Acting Drug Delivery Technologies Market for Long Acting Hydrogels, 2023-2035 (USD Billion)
Figure 13.16 Long Acting Drug Delivery Technologies Market for Long Acting Microneedles, 2023-2035 (USD Billion)
Figure 13.17 Long Acting Drug Delivery Technologies Market for Chemical Modification, 2023-2035 (USD Billion)
Figure 13.18 Long Acting Drug Delivery Technologies Market for Protein Fusion, 2023-2035 (USD Billion)
Figure 13.19 Long Acting Drug Delivery Technologies Market: Distribution by Compatible Dosage Form, 2023, 2030 and 2035
Figure 13.20 Long Acting Drug Delivery Technologies Market for Injectables, 2023-2035 (USD Billion)
Figure 13.21 Long Acting Drug Delivery Technologies Market for Implantables, 2023-2035 (USD Billion)
Figure 13.22 Long Acting Drug Delivery Technologies Market for Vaginal Dosage Forms, 2023-2035 (USD Billion)
Figure 13.23 Long Acting Drug Delivery Technologies Market for Topical / Transdermal Dosage Forms, 2023-2035 (USD Billion)
Figure 13.24 Long Acting Drug Delivery Technologies Market for Oral Dosage Forms, 2023-2035 (USD Billion)
Figure 13.25 Long Acting Drug Delivery Technologies Market for Other Dosage Forms, 2023-2035 (USD Billion)
Figure 13.26 Long Acting Drug Delivery Technologies Market: Distribution by Type of Molecule Delivered, 2023, 2030 and 2035
Figure 13.27 Long Acting Drug Delivery Technologies Market for Small Molecules, 2023-2035 (USD Billion)
Figure 13.28 Long Acting Drug Delivery Technologies Market for Biologics, 2023-2035 (USD Billion)
Figure 13.29 Long Acting Drug Delivery Technologies Market for Other Molecules, 2023-2035 (USD Billion)
Figure 13.30 Long Acting Drug Delivery Technologies Market: Distribution by Type of Material Used, 2023, 2030 and 2035
Figure 13.31 Long Acting Drug Delivery Technologies Market for Polymer based, 2023-2035 (USD Billion)
Figure 13.32 Long Acting Drug Delivery Technologies Market for Non-polymer based, 2023-2035 (USD Billion)
Figure 13.33 Long Acting Drug Delivery Technologies Market: Distribution by Region, 2023, 2030 and 2035
Figure 13.34 Long Acting Drug Delivery Technologies Market in North America, 2023-2035 (USD Billion)
Figure 13.35 Long Acting Drug Delivery Technologies Market in Europe, 2023-2035 (USD Billion)
Figure 13.36 Long Acting Drug Delivery Technologies Market in Asia-Pacific, 2023-2035 (USD Billion)
Figure 13.37 Long Acting Drug Delivery Technologies Market in Middle East and North Africa, 2023-2035 (USD Billion)
Figure 13.38 Global Long Acting Drug Delivery Services Market, 2023-2035
Figure 13.39 Long Acting Drug Delivery Services Market: Distribution by Compatible Dosage Form, 2023, 2030 and 2035
Figure 13.40 Long Acting Drug Delivery Services Market for Injectables, 2023-2035
Figure 13.41 Long Acting Drug Delivery Services Market for Implantables, 2023-2035
Figure 13.42 Long Acting Drug Delivery Services Market for Vaginal Dosage Forms, 2023-2035
Figure 13.43 Long Acting Drug Delivery Services Market for Topical / Transdermal Dosage Forms, 2023-2035
Figure 13.44 Long Acting Drug Delivery Services Market for Oral Dosage Forms, 2023-2035
Figure 13.45 Long Acting Drug Delivery Services Market for Other Dosage Forms, 2023-2035
Figure 13.46 Long Acting Drug Delivery Services Market: Distribution by Type of Molecule Supported, 2023, 2030 and 2035
Figure 13.47 Long Acting Drug Delivery Services Market for Small Molecules, 2023-2035
Figure 13.48 Long Acting Drug Delivery Services Market for Biologics, 2023-2035
Figure 13.49 Long Acting Drug Delivery Services Market for Other Molecules, 2023-2035
Figure 13.50 Long Acting Drug Delivery Services Market: Distribution by Region, 2023, 2030 and 2035
Figure 13.51 Long Acting Drug Delivery Services Market in North America, 2023-2035
Figure 13.52 Long Acting Drug Delivery Services Market in Europe, 2023-2035
Figure 13.53 Long Acting Drug Delivery Services Market in Asia-Pacific, 2023-2035
Figure 14.1 Concluding Remarks: Overall Technology Landscape
Figure 14.2 Concluding Remarks: Overall Service Providers Landscape
Figure 14.3 Concluding Remarks: Partnerships and Collaborations
Figure 14.4 Concluding Remarks: Publication Analysis
Figure 14.5 Concluding Remarks: Patent Analysis
Figure 14.6 Concluding Remarks: Grant Analysis
Figure 14.7 Concluding Remarks: Market Forecast and Opportunity Analysis (Technology)
Figure 14.8 Concluding Remarks: Market Forecast and Opportunity Analysis (Service)
List Of Tables
Table 4.1 LADD Technologies: Information on Principle
Table 4.2 LADD Technologies: Information on Strategy
Table 4.3 LADD Technologies: Information on Type of Material Used
Table 4.4 LADD Technologies: Information on Compatible Dosage Form(s)
Table 4.5 LADD Technologies: Information on Extended Dosing Interval(s)
Table 4.6 LADD Technologies: Information on Type of Molecule(s) Delivered
Table 4.7 LADD Technologies: Information on Highest Phase of Development
Table 4.8 LADD Technologies: Information on Approved Drugs
Table 4.9 LADD Technologies: Information on Therapeutic Area(s)
Table 4.10 LADD Technologies: List of Technology Developers
Table 5.1 LADD Contract Service Providers: List of Service Providers
Table 5.2 LADD Contract Service Providers: Information on Scale of Operation
Table 5.3 LADD Contract Service Providers: Information on Compatible Dosage Form(s)
Table 5.4 LADD Contract Service Providers: Information on Service(s) Offered
Table 5.5 LADD Contract Service Providers: Information on Type of Molecule(s) Supported
Table 8.1 List of Companies Profiled
Table 8.2 Adare Pharma Solutions: Company Overview
Table 8.3 Adare Pharma Solutions: Technology Portfolio
Table 8.4 Adare Pharma Solutions: Recent Developments and Future Outlook
Table 8.5 AMW: Company Overview
Table 8.6 AMW: Technology Portfolio
Table 8.7 AMW: Recent Developments and Future Outlook
Table 8.8 Bostal Drug Delivery: Company Overview
Table 8.9 Bostal Drug Delivery: Technology Portfolio
Table 8.10 Creative Biolabs: Company Overview
Table 8.11 Creative Biolabs: Technology Portfolio
Table 8.12 Creative Biolabs: Recent Developments and Future Outlook
Table 8.13 ForDoz Pharma: Company Overview
Table 8.14 ForDoz Pharma: Technology Portfolio
Table 8.15 ForDoz Pharma: Recent Developments and Future Outlook
Table 8.16 InnoCore Pharmaceuticals: Company Overview
Table 8.17 InnoCore Pharmaceuticals: Technology Portfolio
Table 8.18 InnoCore Pharmaceuticals: Recent Developments and Future Outlook
Table 8.19 Integral BioSystems: Company Overview
Table 8.20 Integral BioSystems: Technology Portfolio
Table 8.21 Integral BioSystems: Recent Developments and Future Outlook
Table 8.22 LATITUDE Pharmaceuticals: Company Overview
Table 8.23 LATITUDE Pharmaceuticals: Technology Portfolio
Table 8.24 Navin Saxena Research and Technology Centre (NSRT): Company Overview
Table 8.25 Navin Saxena Research and Technology Centre (NSRT): Technology Portfolio
Table 8.26 Samyang Biopharm: Company Overview
Table 8.27 Samyang Biopharm: Technology Portfolio
Table 8.28 Samyang Biopharm: Recent Developments and Future Outlook
Table 9.1 Partnerships and Collaborations: Information on Year of Agreement, Type of Partnership and Partner, 2018-2022
Table 9.2 Partnerships and Collaborations: Information on Type of Agreement (Country-wise and Region-wise), 2018-2022
Table 11.1 Patent Analysis: Top CPC Sections
Table 11.2 Patent Analysis: Top CPC Symbols
Table 11.3 Patent Analysis: List of Top CPC Codes
Table 11.4 Patent Analysis: Categorizations based on Weighted Valuation Scores
Table 11.5 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 13.1 Long Acting Drug Delivery Technologies: Average Upfront Payment and Average Milestone Payment, 2018-2022 (USD Million)
Table 16.1 LADD Technologies: Distribution by Principle
Table 16.2 LADD Technologies: Distribution by Strategy
Table 16.3 LADD Technologies: Distribution by Type of Material Used
Table 16.4 LADD Technologies: Distribution by Compatible Dosage Form(s)
Table 16.5 LADD Technologies: Distribution by Extended Dosing Interval(s)
Table 16.6 LADD Technologies: Distribution by Type of Molecule(s) Delivered
Table 16.7 LADD Technologies: Distribution by Highest Phase of Development
Table 16.8 LADD Technologies: Distribution by Number of Approved Drugs
Table 16.9 LADD Technologies: Distribution by Therapeutic Area(s)
Table 16.10 LADD Technology Developers: Distribution by Year of Establishment
Table 16.11 LADD Technology Developers: Distribution by Company Size
Table 16.12 LADD Technology Developers: Distribution by Location of Headquarters
Table 16.13 Most Active Players: Distribution by Number of Technologies
Table 16.14 LADD Contract Service Providers: Distribution by Year of Establishment
Table 16.15 LADD Contract Service Providers: Distribution by Company Size
Table 16.16 LADD Contract Service Providers: Distribution by Location of Headquarters
Table 16.17 LADD Contract Service Providers: Distribution by Company Size and Location of Headquarters
Table 16.18 LADD Contract Service Providers: Distribution by Location of Facilities
Table 16.19 LADD Contract Service Providers: Distribution by Type of Service Provider(s)
Table 16.20 LADD Contract Service Providers: Distribution by Scale of Operation
Table 16.21 LADD Contract Service Providers: Distribution by Compatible Dosage Form(s)
Table 16.22 LADD Contract Service Providers: Distribution by Scale of Operation and Compatible Dosage Form(s)
Table 16.23 LADD Contract Service Providers: Distribution by Service(s) Offered
Table 16.24 LADD Contract Service Providers: Distribution by Company Size and Service(s) Offered
Table 16.25 LADD Contract Service Providers: Distribution by Year of Establishment, Location of Headquarters and Service(s) Offered
Table 16.26 LADD Contract Service Providers: Distribution by Type of Molecule(s) Supported
Table 16.27 LADD Contract Service Providers: Distribution by Type of Service Provider(s) and Type of Molecule(s) Supported
Table 16.28 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2022
Table 16.29 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.30 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 16.31 Partnerships and Collaborations: Distribution by Type of Partner
Table 16.32 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Table 16.33 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Headquarters of Partner
Table 16.34 Most Active Players: Distribution by Number of Partnerships
Table 16.35 Partnerships and Collaborations: Regional Distribution
Table 16.36 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 16.37 Partnerships and Collaborations: Local and International Deals
Table 16.38 Publication Analysis: Cumulative Year-wise Trend, 2017-2022
Table 16.39 Publication Analysis: Distribution by Type of Publication
Table 16.40 Most Popular Journals: Distribution by Number of Publications
Table 16.41 Most Popular Publishers: Distribution by Number of Publications
Table 16.42 Most Popular Copyright Holders: Distribution by Number of Publications
Table 16.43 Key Funding Institutes: Distribution by Number of Publications
Table 16.44 Patent Analysis: Distribution by Type of Patent
Table 16.45 Patent Analysis: Cumulative Distribution by Publication Year, 2018-2022
Table 16.46 Patent Analysis: Distribution by Type of Patent and Publication Year
Table 16.47 Patent Analysis: Distribution by Geography
Table 16.48 Patent Analysis: Distribution by CPC Symbols
Table 16.49 Leading Industry Players: Distribution by Number of Patents
Table 16.50 Patent Analysis: Cumulative Distribution by Type of Organization
Table 16.51 Leading Industrial Players: Benchmarking by Patent Characteristics (CPC Codes)
Table 16.52 Patent Analysis: Distribution by Patent Age (2018-2022)
Table 16.53 Grant Analysis: Cumulative Trend by Year of Grant, 2018-2022
Table 16.54 Grant Analysis: Distribution by Cumulative Amount Awarded (USD Million), 2018-2022
Table 16.55 Grant Analysis: Distribution by Support Period
Table 16.56 Grant Analysis: Distribution by Support Period and Funding Institute Center
Table 16.57 Grant Analysis: Distribution by Type of Grant Application
Table 16.58 Grant Analysis: Distribution by Purpose of Grant Award
Table 16.59 Grant Analysis: Distribution by Activity Code
Table 16.60 Grant Analysis: Distribution by Study Section Involved
Table 16.61 Popular NIH Departments: Distribution by Number of Grants
Table 16.62 Grant Analysis: Distribution by Type of Recipient Organization
Table 16.63 Prominent Program Officers: Distribution by Number of Grants
Table 16.64 Popular Recipient Organizations: Distribution by Number of Grants
Table 16.65 Popular Recipient Organization: Distribution by Grant Amount (USD Million)
Table 16.66 Grant Analysis: Distribution by Region of Recipient Organization
Table 16.67 Global Long Acting Drug Delivery Technologies Market, 2023-2035 (USD Billion)
Table 16.68 Long Acting Drug Delivery Technologies Market: Distribution by Type of Payment Model Employed, 2023, 2030 and 2035
Table 16.69 Long Acting Drug Delivery Technologies Market for Upfront Payment, 2023-2035 (USD Billion)
Table 16.70 Long Acting Drug Delivery Technologies Market for Milestone Payment, 2023-2035 (USD Billion)
Table 16.71 Long Acting Drug Delivery Technologies Market: Distribution by Principle, 2023, 2030 and 2035
Table 16.72 Long Acting Drug Delivery Technologies Market for Manipulation of Drug Release from Delivery Systems, 2023-2035 (USD Billion)
Table 16.73 Long Acting Drug Delivery Technologies Market for Manipulation of In Vivo Clearance, 2023-2035 (USD Billion)
Table 16.74 Long Acting Drug Delivery Technologies Market: Distribution by Strategy, 2023, 2030 and 2035
Table 16.75 Long Acting Drug Delivery Technologies Market for Micro-encapsulation, 2023-2035 (USD Billion)
Table 16.76 Long Acting Drug Delivery Technologies Market for Long Acting Implants, 2023-2035 (USD Billion)
Table 16.77 Long Acting Drug Delivery Technologies Market for Multivesicular Liposomes, 2023-2035
Table 16.78 Long Acting Drug Delivery Technologies Market for Nanocrystal Suspensions, 2023-2035 (USD Billion)
Table 16.79 Long Acting Drug Delivery Technologies Market for Long Acting Hydrogels, 2023-2035 (USD Billion)
Table 16.80 Long Acting Drug Delivery Technologies Market for Long Acting Microneedles, 2023-2035 (USD Billion)
Table 16.81 Long Acting Drug Delivery Technologies Market for Chemical Modification, 2023-2035 (USD Billion)
Table 16.82 Long Acting Drug Delivery Technologies Market for Protein Fusion, 2023-2035 (USD Billion)
Table 16.83 Long Acting Drug Delivery Technologies Market: Distribution by Compatible Dosage Form, 2023, 2030 and 2035
Table 16.84 Long Acting Drug Delivery Technologies Market for Injectables, 2023-2035 (USD Billion)
Table 16.85 Long Acting Drug Delivery Technologies Market for Implantables, 2023-2035 (USD Billion)
Table 16.86 Long Acting Drug Delivery Technologies Market for Vaginal Dosage Forms, 2023-2035 (USD Billion)
Table 16.87 Long Acting Drug Delivery Technologies Market for Topical / Transdermal Dosage Forms, 2023-2035 (USD Billion)
Table 16.88 Long Acting Drug Delivery Technologies Market for Oral Dosage Forms, 2023-2035 (USD Billion)
Table 16.89 Long Acting Drug Delivery Technologies Market for Other Dosage Forms, 2023-2035 (USD Billion)
Table 16.90 Long Acting Drug Delivery Technologies Market: Distribution by Type of Molecule Delivered, 2023, 2030 and 2035
Table 16.91 Long Acting Drug Delivery Technologies Market for Small Molecules, 2023-2035 (USD Billion)
Table 16.92 Long Acting Drug Delivery Technologies Market for Biologics, 2023-2035 (USD Billion)
Table 16.93 Long Acting Drug Delivery Technologies Market for Other Molecules, 2023-2035 (USD Billion)
Table 16.94 Long Acting Drug Delivery Technologies Market: Distribution by Type of Material Used, 2023, 2030 and 2035
Table 16.95 Long Acting Drug Delivery Technologies Market for Polymer based, 2023-2035 (USD Billion)
Table 16.96 Long Acting Drug Delivery Technologies Market for Non-polymer based, 2023-2035 (USD Billion)
Table 16.97 Long Acting Drug Delivery Technologies Market: Distribution by Region, 2023, 2030 and 2035
Table 16.98 Long Acting Drug Delivery Technologies Market in North America, 2023-2035 (USD Billion)
Table 16.99 Long Acting Drug Delivery Technologies Market in Europe, 2023-2035 (USD Billion)
Table 16.100 Long Acting Drug Delivery Technologies Market in Asia-Pacific, 2023-2035 (USD Billion)
Table 16.101 Long Acting Drug Delivery Technologies Market in Middle East and North Africa, 2023-2035 (USD Billion)
Table 16.102 Global Long Acting Drug Delivery Services Market, 2023-2035
Table 16.103 Long Acting Drug Delivery Services Market: Distribution by Compatible Dosage Form, 2023, 2030 and 2035
Table 16.104 Long Acting Drug Delivery Services Market for Injectables, 2023-2035
Table 16.105 Long Acting Drug Delivery Services Market for Implantables, 2023-2035
Table 16.106 Long Acting Drug Delivery Services Market for Vaginal Dosage Forms, 2023-2035
Table 16.107 Long Acting Drug Delivery Services Market for Topical / Transdermal Dosage Forms, 2023-2035
Table 16.108 Long Acting Drug Delivery Services Market for Oral Dosage Forms, 2023-2035
Table 16.109 Long Acting Drug Delivery Services Market for Other Dosage Forms, 2023-2035
Table 16.110 Long Acting Drug Delivery Services Market: Distribution by Type of Molecule Supported, 2023, 2030 and 2035
Table 16.111 Long Acting Drug Delivery Services Market for Small Molecules, 2023-2035
Table 16.112 Long Acting Drug Delivery Services Market for Biologics, 2023-2035
Table 16.113 Long Acting Drug Delivery Services Market for Other Molecules, 2023-2035
Table 16.114 Long Acting Drug Delivery Services Market: Distribution by Region, 2023, 2030 and 2035
Table 16.115 Long Acting Drug Delivery Services Market in North America, 2023-2035
Table 16.116 Long Acting Drug Delivery Services Market in Europe, 2023-2035
Table 16.117 Long Acting Drug Delivery Services Market in Asia-Pacific, 2023-2035
Please reach out to our team for the details.
Source 1: https://pubmed.ncbi.nlm.nih.gov/35363574/
Source 2: https://www.nih.gov/news-events/news-releases/nih-celebrates-fda-approval-long-acting-injectable-drug-hiv-prevention